Triple Negative Breast Cancer – An Overview

Triple Negative Breast Cancer (TNBC) is a heterogeneous disease that based on immunohistochemistry (IHC) is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. TNBC is typically observed in young AA women and Hispanic wom...

Descripción completa

Detalles Bibliográficos
Autores principales: Aysola, Kartik, Desai, Akshata, Welch, Crystal, Xu, Jingyao, Qin, Yunlong, Reddy, Vaishali, Matthews, Roland, Owens, Charlotte, Okoli, Joel, Beech, Derrick J, Piyathilake, Chandrika J, Reddy, Shyam P, Rao, Veena N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181680/
https://www.ncbi.nlm.nih.gov/pubmed/25285241
http://dx.doi.org/10.4172/2161-1041.S2-001
Descripción
Sumario:Triple Negative Breast Cancer (TNBC) is a heterogeneous disease that based on immunohistochemistry (IHC) is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. TNBC is typically observed in young AA women and Hispanic women who carry a mutation in the BRCA1 gene. TNBC is characterized by a distinct molecular profile, aggressive nature and lack of targeted therapies. The purpose of this article is to review the current and future novel signalling pathways as therapeutic approaches to TNBC. Recent Identification of a new BRCA1 trafficking pathway holds promise in the future for the development of targeted therapies for TNBC.

Ejemplares similares